Dalton Receives Compliant Rating From Health Canada
News May 27, 2016
Dalton Pharma Services, a leading Contract Development and Manufacturing Organization, is proud to announce that it has successfully completed another Health Canada inspection and has received a compliant rating from the Health Products and Food Branch Inspectorate of Health Canada.
The inspection covered the scope of sterile and non-sterile drug products, Active Pharmaceutical Ingredients (API) and laboratory operations, and included clinical products. The compliant rating means that the company has successfully demonstrated these activities are in compliance with the high standards of the Canadian Food and Drugs Act and its associated regulations.
“The successful completion of our Health Canada inspection is the direct result of the hard work and dedication of everyone at Dalton as well as our ongoing commitment to providing the highest quality standards to our clients,” said Peter Pekos, President and CEO.
“I believe this compliant inspection is a direct result of having ingrained GMP and compliance into our core company values. The positive result of this inspection will allow Dalton to improve upon our processes as we strive to consistently provide the highest quality for our clients.” said Karina Lahnakoski, Director of Quality.
As a result of achieving the compliant rating, Dalton will continue to provide manufacturing, filling, packaging and testing services to the pharmaceutical and biotechnology industries. Dalton continues to build an impressive regulatory track record, having now completed 6 successful Health Canada inspections, and will continue to uphold the highest quality standards while serving its clients.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018